NEW YORK — Embark Veterinary, which sells consumer DNA tests for dogs, said on Monday that it has raised $75 million in Series B funding.
The round was led by SoftBank Vision Fund 2 and included participation from previous investors F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital, and Third Kind Venture Capital.
Embark's test analyzes 200,000 genetic markers to provide owners and breeders with information about their dogs' breed, ancestry, health, and disease risk. The Boston-based company, which raised $10 million in a Series A round in early 2019, said it will use the new funding to accelerate the development of its discovery engine to expand its canine genetics database.
Competitors to Embark include Mars Petcare's Wisdom Health, OptiGen, and Paw Print Genetics.